Subscribe to receive the Department of Health’s regular COVID-19 vaccines update.
Who is eligible for which vaccine?
| Vaccine |
Eligible populations |
| AstraZeneca |
People aged 60 years or older
People aged 18–59 years after discussion with a qualified health professional |
| Pfizer |
People aged 12–59 years
Residential aged care workers of any age |
| Moderna |
People aged 12–59 years
Residential aged care workers of any age |
Eligibility criteria have been expanded in some states and territories. Expanded eligibility applies to state/territory vaccination providers.
The Department of Health has confirmed that when a general practice has supply and capacity and priority populations have already been vaccinated, they can administer vaccines as per the expanded state or territory eligibility criteria.
Pharmacists now administering Moderna vaccine
Pharmacists have now started administering the Moderna COVID-19 vaccine.
Moderna is available to people aged 12–59 years.
The recommended interval between two doses of Moderna is 28–42 days.
COVID-19 vaccine information for teens and parents/guardians
A fact sheet is available for you to share with teens and their parents/guardians about COVID-19 vaccines.
Clinical guidance on COVID-19 vaccines
The Australian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on the use of COVID-19 vaccines was last updated on 9 September 2021.
The latest updates include that:
- COVID-19 vaccination is recommended for everyone aged 12 years or older
- the Moderna vaccine is registered for use in people aged 12 years or older
- people with a history of congenital heart disease, cardiac transplant or cardiomyopathy can receive an mRNA COVID-19 vaccine (Pfizer or Moderna) without any precautions
- if a second dose of a COVID-19 vaccine is administered fewer than 14 days after the first dose, this is considered an invalid dose and an additional dose should be administered as a replacement dose
- updated summary information is available on adverse events following COVID-19 vaccines
- updated summary information is available on the effectiveness of COVID-19 vaccines.
COVID-19 vaccine safety surveillance
You can find the latest COVID-19 vaccine weekly safety report (with data on adverse events following immunisation up to 2 September 2021) on the Therapeutic Goods Administration website.
It addresses reporting of thrombosis with thrombocytopenia, immune thrombocytopenia and Guillain-Barre Syndrome after receiving the AstraZeneca vaccine, and myocarditis and pericarditis after receiving the Pfizer vaccine.